With summer in full swing, it’s crucial to wear sunscreen and minimize prolonged sun exposure to help reduce the risk of developing melanoma. This UV Safety Awareness Month, learn more about melanoma risk factors and prevention from Cancer.Net.
ASCO's patient information website -- Cancer.Net (www.cancer.net) -- provides timely, oncologist-approved information to help patients and families make informed health care decisions. All content is subject to a formal peer-review process by the Cancer.Net Editorial Board, composed of more than 150 medical, surgical, radiation, and pediatric oncologists, physician assistants, oncology nurses, social workers, and patient advocates. In addition, ASCO editorial staff reviews the content for easy readability. For more about that process, listen to a March 2016 podcast with Editor In Chief Lidia Schapira, MD. Cancer.Net content is reviewed on an annual basis or as needed. Tell us what you think at email@example.com.
About Alkermes plc
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland , Alkermes plc has an R&D center in Waltham, Massachusetts ; a research and manufacturing facility in Athlone, Ireland ; and a manufacturing facility in Wilmington, Ohio . For more information, please visit Alkermes' website at www.alkermes.com.
Tweet me: With summer in full swing, it’s crucial to wear sunscreen and minimize prolonged sun exposure to help reduce the risk of developing #melanoma. This #UVSafetyAwarenessMonth Learn more about melanoma risk factors and prevention from @CancerDotNet: https://bit.ly/32oxHTA @Alkermes
KEYWORDS: NASDAQ:ALKS, Alkermes, UV Safety, melanoma, skin cancer, cancer.net